nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP1A1—liver cancer	0.327	1	CbGaD
Dapagliflozin—UGT2B7—Epirubicin—liver cancer	0.138	0.349	CbGbCtD
Dapagliflozin—UGT1A9—Sorafenib—liver cancer	0.128	0.323	CbGbCtD
Dapagliflozin—Drug-induced hepatitis—Sorafenib—liver cancer	0.0238	0.229	CcSEcCtD
Dapagliflozin—CYP1A2—Sorafenib—liver cancer	0.0237	0.0599	CbGbCtD
Dapagliflozin—CYP2C9—Sorafenib—liver cancer	0.0214	0.054	CbGbCtD
Dapagliflozin—ABCB1—Sorafenib—liver cancer	0.0208	0.0524	CbGbCtD
Dapagliflozin—CYP2D6—Sorafenib—liver cancer	0.0196	0.0494	CbGbCtD
Dapagliflozin—Drug-induced liver injury—Sorafenib—liver cancer	0.0137	0.131	CcSEcCtD
Dapagliflozin—ABCB1—Doxorubicin—liver cancer	0.0126	0.0318	CbGbCtD
Dapagliflozin—CYP3A4—Sorafenib—liver cancer	0.0124	0.0314	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—liver cancer	0.0119	0.03	CbGbCtD
Dapagliflozin—CYP3A4—Doxorubicin—liver cancer	0.00755	0.019	CbGbCtD
Dapagliflozin—Balanitis—Epirubicin—liver cancer	0.00323	0.031	CcSEcCtD
Dapagliflozin—Balanitis—Doxorubicin—liver cancer	0.00299	0.0287	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Sorafenib—liver cancer	0.00168	0.0161	CcSEcCtD
Dapagliflozin—Canagliflozin—ALB—liver cancer	0.00156	1	CrCbGaD
Dapagliflozin—Hyperphosphataemia—Epirubicin—liver cancer	0.00155	0.0149	CcSEcCtD
Dapagliflozin—Hyperphosphataemia—Doxorubicin—liver cancer	0.00144	0.0138	CcSEcCtD
Dapagliflozin—Neoplasm—Sorafenib—liver cancer	0.0013	0.0125	CcSEcCtD
Dapagliflozin—Hyponatraemia—Sorafenib—liver cancer	0.00105	0.01	CcSEcCtD
Dapagliflozin—Pain in extremity—Sorafenib—liver cancer	0.00104	0.01	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Epirubicin—liver cancer	0.00101	0.00969	CcSEcCtD
Dapagliflozin—Venous thrombosis—Epirubicin—liver cancer	0.000982	0.00944	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Epirubicin—liver cancer	0.00097	0.00932	CcSEcCtD
Dapagliflozin—Dehydration—Sorafenib—liver cancer	0.000968	0.00931	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Doxorubicin—liver cancer	0.000933	0.00897	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Sorafenib—liver cancer	0.000931	0.00895	CcSEcCtD
Dapagliflozin—Venous thrombosis—Doxorubicin—liver cancer	0.000909	0.00873	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Doxorubicin—liver cancer	0.000897	0.00862	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Epirubicin—liver cancer	0.000862	0.00828	CcSEcCtD
Dapagliflozin—Infestation—Sorafenib—liver cancer	0.000802	0.00771	CcSEcCtD
Dapagliflozin—Infestation NOS—Sorafenib—liver cancer	0.000802	0.00771	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Doxorubicin—liver cancer	0.000797	0.00766	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Sorafenib—liver cancer	0.000791	0.0076	CcSEcCtD
Dapagliflozin—Renal failure—Sorafenib—liver cancer	0.000789	0.00758	CcSEcCtD
Dapagliflozin—Myocardial infarction—Sorafenib—liver cancer	0.000787	0.00756	CcSEcCtD
Dapagliflozin—Lung disorder—Epirubicin—liver cancer	0.000749	0.0072	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Sorafenib—liver cancer	0.000711	0.00684	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Sorafenib—liver cancer	0.000708	0.0068	CcSEcCtD
Dapagliflozin—Urethral disorder—Sorafenib—liver cancer	0.000706	0.00679	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—liver cancer	0.000693	0.00666	CcSEcCtD
Dapagliflozin—Fungal infection—Epirubicin—liver cancer	0.000687	0.0066	CcSEcCtD
Dapagliflozin—Fungal infection—Doxorubicin—liver cancer	0.000635	0.00611	CcSEcCtD
Dapagliflozin—Malnutrition—Sorafenib—liver cancer	0.000627	0.00603	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Epirubicin—liver cancer	0.000621	0.00597	CcSEcCtD
Dapagliflozin—Extravasation—Epirubicin—liver cancer	0.000608	0.00584	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—liver cancer	0.000574	0.00552	CcSEcCtD
Dapagliflozin—Angioedema—Sorafenib—liver cancer	0.000573	0.00551	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—liver cancer	0.000572	0.00549	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—liver cancer	0.000562	0.0054	CcSEcCtD
Dapagliflozin—Hypertension—Sorafenib—liver cancer	0.000541	0.0052	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00053	0.0051	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—liver cancer	0.000529	0.00508	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Sorafenib—liver cancer	0.000512	0.00492	CcSEcCtD
Dapagliflozin—Infection—Sorafenib—liver cancer	0.000508	0.00489	CcSEcCtD
Dapagliflozin—Vaginal infection—Epirubicin—liver cancer	0.000501	0.00481	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—liver cancer	0.000501	0.00481	CcSEcCtD
Dapagliflozin—Skin disorder—Sorafenib—liver cancer	0.000497	0.00478	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—liver cancer	0.000479	0.00461	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—liver cancer	0.000463	0.00445	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—liver cancer	0.000463	0.00445	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—liver cancer	0.000447	0.00429	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—liver cancer	0.000444	0.00426	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—liver cancer	0.000442	0.00425	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Sorafenib—liver cancer	0.000442	0.00425	CcSEcCtD
Dapagliflozin—Constipation—Sorafenib—liver cancer	0.000438	0.00421	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—liver cancer	0.000413	0.00397	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—liver cancer	0.000409	0.00393	CcSEcCtD
Dapagliflozin—Urticaria—Sorafenib—liver cancer	0.000407	0.00391	CcSEcCtD
Dapagliflozin—Body temperature increased—Sorafenib—liver cancer	0.000405	0.00389	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—liver cancer	0.000394	0.00379	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—liver cancer	0.000393	0.00377	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—liver cancer	0.000386	0.00371	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—liver cancer	0.000385	0.0037	CcSEcCtD
Dapagliflozin—Hypersensitivity—Sorafenib—liver cancer	0.000377	0.00362	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—liver cancer	0.000365	0.00351	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—liver cancer	0.000363	0.00349	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—liver cancer	0.000361	0.00346	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—liver cancer	0.000358	0.00344	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—liver cancer	0.000358	0.00344	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—liver cancer	0.000356	0.00342	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—liver cancer	0.000351	0.00338	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—liver cancer	0.000344	0.00331	CcSEcCtD
Dapagliflozin—Dizziness—Sorafenib—liver cancer	0.000338	0.00325	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—liver cancer	0.000334	0.00321	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—liver cancer	0.000333	0.0032	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—liver cancer	0.000331	0.00318	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—liver cancer	0.000325	0.00313	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—liver cancer	0.000324	0.00311	CcSEcCtD
Dapagliflozin—Rash—Sorafenib—liver cancer	0.000323	0.0031	CcSEcCtD
Dapagliflozin—Dermatitis—Sorafenib—liver cancer	0.000322	0.0031	CcSEcCtD
Dapagliflozin—Headache—Sorafenib—liver cancer	0.000321	0.00308	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—liver cancer	0.000318	0.00306	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—liver cancer	0.000311	0.00299	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—liver cancer	0.000308	0.00296	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—liver cancer	0.000307	0.00295	CcSEcCtD
Dapagliflozin—Nausea—Sorafenib—liver cancer	0.000304	0.00292	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—liver cancer	0.0003	0.00288	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—liver cancer	0.000297	0.00285	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—liver cancer	0.000297	0.00285	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—liver cancer	0.000292	0.0028	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—liver cancer	0.000288	0.00277	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—liver cancer	0.000288	0.00277	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—liver cancer	0.000284	0.00273	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—liver cancer	0.000274	0.00264	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—liver cancer	0.000274	0.00264	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—liver cancer	0.00027	0.00259	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—liver cancer	0.000267	0.00256	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—liver cancer	0.000263	0.00253	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—liver cancer	0.000262	0.00251	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—liver cancer	0.000261	0.00251	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—liver cancer	0.000243	0.00234	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—liver cancer	0.000242	0.00233	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—liver cancer	0.000241	0.00232	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—liver cancer	0.000232	0.00223	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—liver cancer	0.000224	0.00215	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—liver cancer	0.000214	0.00206	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—liver cancer	0.000207	0.00199	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—liver cancer	0.0002	0.00192	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000196	0.00188	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—liver cancer	0.000195	0.00187	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—liver cancer	0.000189	0.00182	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—liver cancer	0.000189	0.00182	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—liver cancer	0.000188	0.00181	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—liver cancer	0.000185	0.00178	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—liver cancer	0.000184	0.00177	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—liver cancer	0.000183	0.00176	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000181	0.00174	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—liver cancer	0.00018	0.00173	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—liver cancer	0.000177	0.0017	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—liver cancer	0.000175	0.00168	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—liver cancer	0.000175	0.00168	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—liver cancer	0.000174	0.00167	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—liver cancer	0.00017	0.00163	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—liver cancer	0.000169	0.00163	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—liver cancer	0.000164	0.00157	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—liver cancer	0.000163	0.00157	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—liver cancer	0.000162	0.00155	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000151	0.00145	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—liver cancer	0.00015	0.00144	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—liver cancer	0.00015	0.00144	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—liver cancer	0.00015	0.00144	CcSEcCtD
Dapagliflozin—Hypersensitivity—Epirubicin—liver cancer	0.000139	0.00134	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—liver cancer	0.000139	0.00134	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—liver cancer	0.000138	0.00133	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—liver cancer	0.000129	0.00124	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—liver cancer	0.000125	0.0012	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—liver cancer	0.000119	0.00115	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—liver cancer	0.000119	0.00115	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—liver cancer	0.000118	0.00114	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—liver cancer	0.000116	0.00111	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—liver cancer	0.000112	0.00108	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—liver cancer	0.00011	0.00106	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—liver cancer	0.00011	0.00106	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—liver cancer	0.00011	0.00105	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—liver cancer	0.000104	0.000999	CcSEcCtD
Dapagliflozin—CYP2D6—Metabolism—GLUL—liver cancer	1.09e-05	6.37e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CPT1B—liver cancer	1.09e-05	6.37e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GOT2—liver cancer	1.09e-05	6.34e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GLUL—liver cancer	1.08e-05	6.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CPT1B—liver cancer	1.08e-05	6.31e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—HMOX1—liver cancer	1.08e-05	6.29e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PPARA—liver cancer	1.07e-05	6.26e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CRABP1—liver cancer	1.07e-05	6.24e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	1.06e-05	6.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NR1H4—liver cancer	1.05e-05	6.14e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TAT—liver cancer	1.05e-05	6.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NR1H4—liver cancer	1.04e-05	6.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTA3—liver cancer	1.03e-05	6.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTA3—liver cancer	1.03e-05	5.98e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP2E1—liver cancer	1.02e-05	5.96e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	1.01e-05	5.91e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	1.01e-05	5.89e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTM1—liver cancer	1e-05	5.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTA4—liver cancer	1e-05	5.86e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1e-05	5.84e-05	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—AKT1—liver cancer	9.96e-06	5.81e-05	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—AKT1—liver cancer	9.96e-06	5.81e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTA2—liver cancer	9.78e-06	5.71e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	9.62e-06	5.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYCS—liver cancer	9.56e-06	5.58e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP1A1—liver cancer	9.52e-06	5.56e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTA4—liver cancer	9.46e-06	5.52e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTA1—liver cancer	9.44e-06	5.51e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	9.43e-06	5.5e-05	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CA—liver cancer	9.41e-06	5.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GOT1—liver cancer	9.38e-06	5.47e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GGT1—liver cancer	9.38e-06	5.47e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTA4—liver cancer	9.38e-06	5.47e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	9.35e-06	5.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HPGDS—liver cancer	9.34e-06	5.45e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NAT2—liver cancer	9.33e-06	5.45e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	9.28e-06	5.42e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CPT1B—liver cancer	9.24e-06	5.39e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GLUL—liver cancer	9.24e-06	5.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTA2—liver cancer	9.22e-06	5.38e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CG—liver cancer	9.18e-06	5.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	9.16e-06	5.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTA2—liver cancer	9.14e-06	5.33e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALDOB—liver cancer	8.95e-06	5.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NR1H4—liver cancer	8.91e-06	5.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTA1—liver cancer	8.89e-06	5.19e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—MTHFR—liver cancer	8.88e-06	5.18e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PPARG—liver cancer	8.86e-06	5.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTA1—liver cancer	8.81e-06	5.14e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NAT2—liver cancer	8.79e-06	5.13e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTA3—liver cancer	8.76e-06	5.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NAT2—liver cancer	8.72e-06	5.09e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPARA—liver cancer	8.71e-06	5.08e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	8.59e-06	5.02e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CRABP1—liver cancer	8.53e-06	4.98e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	8.53e-06	4.98e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.46e-06	4.94e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALDOB—liver cancer	8.43e-06	4.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTP1—liver cancer	8.43e-06	4.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.38e-06	4.89e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALDOB—liver cancer	8.36e-06	4.88e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.35e-06	4.87e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PSMD10—liver cancer	8.32e-06	4.86e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PSMA4—liver cancer	8.32e-06	4.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	8.31e-06	4.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—HMOX1—liver cancer	8.31e-06	4.85e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GOT2—liver cancer	8.1e-06	4.73e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CD—liver cancer	8.07e-06	4.71e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CRABP1—liver cancer	8.04e-06	4.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTA4—liver cancer	8.01e-06	4.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CRABP1—liver cancer	7.97e-06	4.65e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ALB—liver cancer	7.97e-06	4.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7.83e-06	4.57e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.82e-06	4.57e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTA2—liver cancer	7.81e-06	4.56e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTM1—liver cancer	7.74e-06	4.52e-05	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—liver cancer	7.69e-06	4.49e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP2E1—liver cancer	7.61e-06	4.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTA1—liver cancer	7.53e-06	4.4e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HPGDS—liver cancer	7.46e-06	4.35e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CG—liver cancer	7.46e-06	4.35e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NAT2—liver cancer	7.45e-06	4.35e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.37e-06	4.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP1A1—liver cancer	7.34e-06	4.28e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPARG—liver cancer	7.2e-06	4.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	7.18e-06	4.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	7.16e-06	4.18e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALDOB—liver cancer	7.14e-06	4.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GLUL—liver cancer	7.13e-06	4.16e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CPT1B—liver cancer	7.13e-06	4.16e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYCS—liver cancer	7.12e-06	4.16e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CB—liver cancer	7.03e-06	4.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HPGDS—liver cancer	7.03e-06	4.1e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	7.02e-06	4.1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GGT1—liver cancer	6.99e-06	4.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GOT1—liver cancer	6.99e-06	4.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HPGDS—liver cancer	6.97e-06	4.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.93e-06	4.04e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NR1H4—liver cancer	6.88e-06	4.01e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—MTHFR—liver cancer	6.84e-06	3.99e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CRABP1—liver cancer	6.81e-06	3.98e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA3—liver cancer	6.76e-06	3.95e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARA—liver cancer	6.71e-06	3.92e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PSMA4—liver cancer	6.65e-06	3.88e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PSMD10—liver cancer	6.65e-06	3.88e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CD—liver cancer	6.56e-06	3.83e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ALB—liver cancer	6.47e-06	3.78e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GOT2—liver cancer	6.47e-06	3.77e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	6.34e-06	3.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.31e-06	3.68e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTP1—liver cancer	6.28e-06	3.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PSMA4—liver cancer	6.26e-06	3.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PSMD10—liver cancer	6.26e-06	3.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.23e-06	3.64e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PSMD10—liver cancer	6.21e-06	3.62e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PSMA4—liver cancer	6.21e-06	3.62e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HMOX1—liver cancer	6.19e-06	3.61e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA4—liver cancer	6.18e-06	3.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.13e-06	3.58e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GOT2—liver cancer	6.09e-06	3.56e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP2E1—liver cancer	6.08e-06	3.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GOT2—liver cancer	6.04e-06	3.53e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA2—liver cancer	6.03e-06	3.52e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HPGDS—liver cancer	5.95e-06	3.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.92e-06	3.45e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA1—liver cancer	5.81e-06	3.39e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—liver cancer	5.77e-06	3.37e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—liver cancer	5.75e-06	3.36e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NAT2—liver cancer	5.75e-06	3.35e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	5.73e-06	3.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP2E1—liver cancer	5.73e-06	3.34e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CB—liver cancer	5.72e-06	3.34e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYCS—liver cancer	5.69e-06	3.32e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP2E1—liver cancer	5.68e-06	3.32e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GOT1—liver cancer	5.58e-06	3.26e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GGT1—liver cancer	5.58e-06	3.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARG—liver cancer	5.55e-06	3.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALDOB—liver cancer	5.51e-06	3.22e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.5e-06	3.21e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.39e-06	3.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYCS—liver cancer	5.36e-06	3.13e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.32e-06	3.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYCS—liver cancer	5.31e-06	3.1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PSMA4—liver cancer	5.31e-06	3.1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PSMD10—liver cancer	5.31e-06	3.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GGT1—liver cancer	5.26e-06	3.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GOT1—liver cancer	5.26e-06	3.07e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CRABP1—liver cancer	5.26e-06	3.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GOT1—liver cancer	5.22e-06	3.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GGT1—liver cancer	5.22e-06	3.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GOT2—liver cancer	5.16e-06	3.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—liver cancer	5.1e-06	2.98e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CD—liver cancer	5.05e-06	2.95e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—liver cancer	5.01e-06	2.93e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARA—liver cancer	5e-06	2.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALB—liver cancer	4.99e-06	2.91e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HMOX1—liver cancer	4.95e-06	2.89e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2E1—liver cancer	4.85e-06	2.83e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—liver cancer	4.73e-06	2.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.7e-06	2.74e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—liver cancer	4.68e-06	2.73e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HMOX1—liver cancer	4.66e-06	2.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HMOX1—liver cancer	4.62e-06	2.7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—liver cancer	4.61e-06	2.69e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HPGDS—liver cancer	4.6e-06	2.68e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYCS—liver cancer	4.54e-06	2.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.49e-06	2.62e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GGT1—liver cancer	4.46e-06	2.6e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GOT1—liver cancer	4.46e-06	2.6e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CB—liver cancer	4.41e-06	2.57e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1A1—liver cancer	4.37e-06	2.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—liver cancer	4.34e-06	2.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—liver cancer	4.3e-06	2.51e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—liver cancer	4.29e-06	2.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—liver cancer	4.28e-06	2.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARG—liver cancer	4.13e-06	2.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1A1—liver cancer	4.12e-06	2.4e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PSMA4—liver cancer	4.1e-06	2.39e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PSMD10—liver cancer	4.1e-06	2.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1A1—liver cancer	4.08e-06	2.38e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—liver cancer	4.07e-06	2.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—liver cancer	4e-06	2.34e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARA—liver cancer	4e-06	2.33e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GOT2—liver cancer	3.98e-06	2.33e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HMOX1—liver cancer	3.95e-06	2.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—liver cancer	3.84e-06	2.24e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—liver cancer	3.8e-06	2.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CD—liver cancer	3.77e-06	2.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARA—liver cancer	3.76e-06	2.2e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2E1—liver cancer	3.75e-06	2.19e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARA—liver cancer	3.73e-06	2.18e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALB—liver cancer	3.72e-06	2.17e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—liver cancer	3.68e-06	2.15e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYCS—liver cancer	3.51e-06	2.05e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—liver cancer	3.5e-06	2.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1A1—liver cancer	3.49e-06	2.04e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—liver cancer	3.48e-06	2.03e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GGT1—liver cancer	3.44e-06	2.01e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GOT1—liver cancer	3.44e-06	2.01e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—liver cancer	3.42e-06	2e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.35e-06	1.96e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARG—liver cancer	3.3e-06	1.93e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CB—liver cancer	3.28e-06	1.92e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—liver cancer	3.25e-06	1.9e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—liver cancer	3.22e-06	1.88e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—liver cancer	3.2e-06	1.87e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARA—liver cancer	3.19e-06	1.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARG—liver cancer	3.11e-06	1.82e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—liver cancer	3.09e-06	1.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARG—liver cancer	3.09e-06	1.8e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMOX1—liver cancer	3.05e-06	1.78e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CD—liver cancer	3.01e-06	1.76e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALB—liver cancer	2.97e-06	1.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.86e-06	1.67e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—liver cancer	2.85e-06	1.66e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—liver cancer	2.84e-06	1.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CD—liver cancer	2.83e-06	1.65e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CD—liver cancer	2.81e-06	1.64e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALB—liver cancer	2.8e-06	1.63e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALB—liver cancer	2.77e-06	1.62e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—liver cancer	2.73e-06	1.59e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1A1—liver cancer	2.69e-06	1.57e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—liver cancer	2.69e-06	1.57e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARG—liver cancer	2.64e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CB—liver cancer	2.62e-06	1.53e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—liver cancer	2.51e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CB—liver cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARA—liver cancer	2.46e-06	1.44e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CB—liver cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CD—liver cancer	2.4e-06	1.4e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALB—liver cancer	2.37e-06	1.38e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—liver cancer	2.19e-06	1.28e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—liver cancer	2.11e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CB—liver cancer	2.09e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARG—liver cancer	2.03e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—liver cancer	2e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CD—liver cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALB—liver cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—liver cancer	1.63e-06	9.54e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CB—liver cancer	1.62e-06	9.43e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—liver cancer	1.6e-06	9.33e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—liver cancer	1.51e-06	8.79e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—liver cancer	1.49e-06	8.71e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—liver cancer	1.31e-06	7.62e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—liver cancer	1.28e-06	7.45e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—liver cancer	1.23e-06	7.18e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—liver cancer	1.22e-06	7.12e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—liver cancer	1.04e-06	6.08e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—liver cancer	9.85e-07	5.75e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—liver cancer	8.04e-07	4.69e-06	CbGpPWpGaD
